Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signal

Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets.

Lilly established itself as a player in the nascent radiopharma space by acquiring Point Biopharma for $1.4 billion late last year. The takeover included a manufacturing plant, R&D campus and pipeline led by a PSMA-targeted radioligand therapy, giving Lilly a launchpad for a broader push to make the modality a key part of its oncology pipeline.